UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

SCHEDULE 13G/A

 

Under the Securities Exchange Act of 1934

(Amendment No. 1)*



Larkspur Health Acquisition Corp.

(Name of Issuer)

 

Units, each consisting of one share of Class A Common Stock and three-fourths of one Redeemable Warrant

(Title of Class of Securities)

 

51724W206

(CUSIP Number)

 

 

December 31, 2022
(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

x Rule 13d-1(b)

o Rule 13d-1(c)

o Rule 13d-1(d)

 

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 
 

CUSIP No.  51724W206
 SCHEDULE 13G/A
Page 2 of 8 Pages

 

         
1
NAME OF REPORTING PERSONS
 
Lighthouse Investment Partners, LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o
(b) o
 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
0
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
0
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
0
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
0.0%
12
TYPE OF REPORTING PERSON
 
IA

 
 

CUSIP No.  51724W206
 SCHEDULE 13G/A
Page 3 of 8 Pages

 

         
1
NAME OF REPORTING PERSONS
 
MAP 136 Segregated Portfolio, a segregated portfolio of LMA SPC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o
(b) o
 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Cayman Islands
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
0
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
0
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
0
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
0.0%
12
TYPE OF REPORTING PERSON
 
FI

 
 

 

CUSIP No. 51724W206
 SCHEDULE 13G/A
Page 4 of 8 Pages

 

Item 1.(a) Name of Issuer

Larkspur Health Acquisition Corp.

Item 1.(b) Address of Issuer’s Principal Executive Offices

100 Somerset Corporate Blvd.

2nd Floor, Bridgewater, New Jersey 08807

Item 2.(a) Name of Person Filing:

 

This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”)

 

i) Lighthouse Investment Partners, LLC (“Lighthouse”) 

ii) MAP 136 Segregated Portfolio, a segregated portfolio of LMA SPC (“MAP 136”)

  

This Statement relates to the Issuer’s shares of common stock (“Shares”) directly beneficially owned by MAP 136. Lighthouse serves as the investment manager of MAP 136. Because Lighthouse may be deemed to control MAP 136, Lighthouse may be deemed to beneficially own, and to have the power to vote or direct the vote of, and the power to direct the disposition of the Issuer’s Shares reported herein.

 

Address of Principal Business Office:

3801 PGA Boulevard, Suite 500, Palm Beach Gardens, FL 33410

 

Citizenship:

MAP 136 is a segregated portfolio of LMA SPC, a Cayman Islands segregated portfolio company. Lighthouse is a Delaware limited liability company.

  

Item 2.(d) Title of Class of Securities

Units, each consisting of one share of Class A Common Stock and three-fourths of one Redeemable Warrant

 

Item 2.(e) CUSIP No.:

51724W206

 

CUSIP No.  51724W206
 SCHEDULE 13G/A
Page 5 of 8 Pages

 

 

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

  (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
 
  (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
 
  (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
 
  (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
 
  (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
 
  (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
 
  (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
 
  (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
 
  (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
 
  (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
 
  (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
       

 

CUSIP No. 51724W206
 SCHEDULE 13G/A
Page 6 of 8 Pages

 

 

Item 4. Ownership

(a) Amount Beneficially Owned: As of December 31, 2022, each of the Reporting Persons may be deemed the beneficial owner of 0 Shares.

 

  (b) Percent of Class: As of December 31, 2022, each of the Reporting Persons may be deemed the beneficial owner of approximately 0.0% of Shares outstanding.

 

  (c) Number of shares to which the person has:

 

  (i) Sole power to vote or to direct the vote: 0

 

  (ii) Shared power to vote or to direct the vote: 0

 

  (iii) Sole power to dispose or to direct the disposition of: 0

 

  (iv) Shared power to dispose or to direct the disposition of 0

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

Item 6. Ownership of More Than Five Percent on Behalf of Another Person

Not Applicable.

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Not Applicable.

Item 8. Identification and Classification of Members of the Group

Not Applicable.

Item 9. Notice of Dissolution of Group 

Not Applicable.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 
CUSIP No. 51724W206
 SCHEDULE 13G/A
Page 7 of 8 Pages

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 14, 2023

 

 

 

 

Lighthouse Investment Partners, LLC

       
  By:  /s/ Robert P. Swan
    Robert P. Swan, Vice President
       
 

MAP 136 Segregated Portfolio, a segregated portfolio of LMA SPC

       
  By:  /s/ Robert P. Swan
    Robert P. Swan, Director

 
CUSIP No. 51724W206
 SCHEDULE 13G/A
Page 8 of 8 Pages

 

Exhibit I

 

JOINT FILING STATEMENT

 

PURSUANT TO RULE 13d-1(k)

 

The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

 

Dated: February 14, 2023

 

 

Lighthouse Investment Partners, LLC

       
  By:  /s/ Robert P. Swan
    Robert P. Swan, Vice President
       
 

MAP 136 Segregated Portfolio, a segregated portfolio of LMA SPC

       
  By:  /s/ Robert P. Swan
    Robert P. Swan, Director
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Nov 2023 to Dec 2023 Click Here for more ZyVersa Therapeutics Charts.
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Dec 2022 to Dec 2023 Click Here for more ZyVersa Therapeutics Charts.

Zyversa Therapeutics, Inc. News

Form 424B4 - Prospectus [Rule 424(b)(4)]
Saturday 9 December 2023 (2 days ago) • Edgar (US Regulatory)
ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes
Friday 8 December 2023 (4 days ago) • GlobeNewswire Inc.
Form EFFECT - Notice of Effectiveness
Thursday 7 December 2023 (4 days ago) • Edgar (US Regulatory)
ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering
Thursday 7 December 2023 (4 days ago) • GlobeNewswire Inc.
ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways
Wednesday 6 December 2023 (5 days ago) • GlobeNewswire Inc.
Form 8-K - Current report
Friday 1 December 2023 (2 weeks ago) • Edgar (US Regulatory)
ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock
Friday 1 December 2023 (2 weeks ago) • GlobeNewswire Inc.
Form 424B3 - Prospectus [Rule 424(b)(3)]
Tuesday 21 November 2023 (3 weeks ago) • Edgar (US Regulatory)
Form 8-K - Current report
Saturday 18 November 2023 (3 weeks ago) • Edgar (US Regulatory)
ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results
Wednesday 15 November 2023 (4 weeks ago) • GlobeNewswire Inc.
ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model
Thursday 9 November 2023 (1 month ago) • GlobeNewswire Inc.
ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation
Monday 6 November 2023 (1 month ago) • GlobeNewswire Inc.

More Zyversa Therapeutics, Inc. News Articles